复方丹参滴丸对氯吡格雷抵抗患者血小板聚集功能影响的研究

Effect of compound tanshinone drop pill on platelet aggregation function in patients with clopidogrel resistance

目的观察复方丹参滴丸是否对氯吡格雷抵抗患者的血小板聚集功能有影响。方法既往明确诊断冠心病并坚持口服氯吡格雷1个月以上、因急性冠脉综合征(ACS)入住我院心内科的患者67例,给予复方丹参滴丸口服。观察分别在用药前、服用后7天及30天时ADP诱导检测血小板聚集水平,评估复方丹参滴丸对氯吡格雷抵抗患者血小板聚集功能的影响。结果 67例患者试验过程中无脑出血、消化道出血及泌尿道出血等出血并发症出现,治疗前后常规检查结果比较无明显差异(P>0.05)。联合复方丹参滴丸治疗前、治疗7天和治疗30天时以ADP作为诱导剂检测的血小板聚集水平分别为(8.9±3.7)Ω、(4.2±3.1)Ω和(4.3±2.8)Ω,药物干预前后血小板聚集水平比较差异有统计学意义(P<0.05)。结论对于氯吡格雷抵抗患者,应用复方丹参滴丸治疗可进一步抑制血小板功能,降低血小板聚集水平,是氯吡格雷抵抗治疗的有益补充。

Objective To investigate whether the compound Tanshinone drop pill have an effect on platelet aggregation function in patients with clopidogrel resistance. Methods Giving oral Compound Tanshinone Drop Pill to 67 patients with acute coronary syndrome （ ACS）, who received clopidogrel more than one month after being diagnosed with coronary heart disease. Measuring ADP-induced platelet aggregation before and after 7-day, 30-day treatment were used to evaluate the effect of Compound Tanshinone Drop Pill on platelet aggregation function in patients with clopidogrel resistanee. Results All 67 patients have no cerebral hemorrhage, gastrointestinal bleeding and urinary tract hemorrhage bleeding complieations in the process of test. There were no significant differences between before and after treatment with respect to routine examination. The levels of ADPinduced platelet aggregation before and after 7-day, 30-day treatment are （8. 9 ± 3.7 ） 1±, （4. 2 ± 3.1 ） f± and （ 4. 3 ± 2. 8 ） It, respectively. There was a statistical significance between before and after treatment with Compound Tanshinone Drop Pill in terms of the level of platelet aggregation （ P 〈 0.05 ） . Conclusion Our study indicate that Compound Tanshinone Drop Pill can contribute to the therapy of elopidogrel resistance by restraint of platelet function and reducing platelet aggregation level.